All Videos Tagged personalized (MedTech I.Q.) - MedTech I.Q.

Informatics: Michael Liebman, CEO, Strategic Medicine, Inc. ... Translating Data Into Better Healthcare

2010-03-08T13:15:37.230Z

In this video, MedTech-IQ member, Michael N. Liebman, President and Managing Director of Strategic Medicine, discusses his company at the 2010 OneMedForum in San Francisco.

Strategic Medicine (SMI) specializes in patient and disease stratification with the end goals of providing better healthcare and identifying unmet clinical needs. The company, based in Kennett Square, Penn., seeks to apply clinical research to a practical, real-world environment. SMI’s products are able to interact directly with electronic medical records or function as stand-alone systems.

It is often difficult to understand why a patient may develop terminal cancer, or why one patient responds to a particular medication while another doesn’t. The concept of personalized or translational medicine, which has been gaining popularity in recent years, seeks to answer questions such as these. Instead of a one-size-fits-all approach to treatment, personalized medicine examines the individual factors that influence the patient’s health, such as genetics, lifestyle, and environment. By looking at the broad scope of the individual’s life, physicians may be able to determine the most effective treatment for the patient.

According to a recent article in BusinessWeek, personalized medicine may also open up new opportunities for pharmaceutical and diagnostic companies, which could target new products to smaller but more responsive groups of patients.

SMI is partnered with the Mayo Clinic on an adaptive knowledge platform that analyzes physicians’ treatment decisions compared to clinical guidelines. By combining data from both sides, the company anticipates that physicians will be able to make more informed treatment decisions, and pharmaceutical or diagnostic companies will be able to identify gaps where a new business opportunity may exist.

Future Vision: Web 2.0 Summit 08

2009-11-06T17:10:39.659Z

The Future of Health:
Marc Hodosh (TED MED, X PRIZE), Anne Wojcicki (23andMe), Carol McCall (Humana Inc.), Daniel Kraft (Stanford Medical School)

Informatics: Personal Genome Computing: Breakthroughs, Risks and Opportunities

2009-09-02T07:04:51.488Z

ChurchillClub
February 02, 2009

"Technology breakthroughs are making DNA sequencing faster and cheaper than ever. In its top ten list of 2008 scientific breakthroughs that broke through with the potential for lasting impact, Scie...
"Technology breakthroughs are making DNA sequencing faster and cheaper than ever. In its top ten list of 2008 scientific breakthroughs that broke through with the potential for lasting impact, Science magazine included technology that has blown the doors off genome sequencing. In Nature magazines list of the top news stories of 2008, "Personal genomics goes mainstream" came in second. With the cost of DNA sequencing plummeting, the emergence of "molecular sequencing" platforms has forever changed the field of genetics.

A new paradigm appears on the horizon. Personal genome information will be used not just for health maintenance, disease diagnosis, and treatment, but will also be the foundation for lifestyle applications from shopping for food, to buying cosmetics, to assessing ones environment and making choices about fabrics, places - even friends.

This panel of Silicon Valley players and innovators of new business models examines the dynamic business and investment opportunities as well as the risks, global competition, regulatory and legal challenges, new individual contributor roles, and leading alliances emerging from Silicon Valley and beyond.

Silicon Valley changed the world as the driving force in the development of computers and the internet. Could we play a similar role in advancing a genome-based economy?". Panelists:

•Linda Avey, Founder, 23andMe.
•David Medina, HP Chief Technologist, Worldwide Health & Life Sciences
•Karoly Nikolich., Dievini Hopp Biotech Holding, CEO of Amnestix
•Andras Pellionisz, founder, International Hologenomics Society and HolGenTech
•Dietrich Stephan, founder, Navigenics, founder of Amnestix

Moderator:
•Phyllis Whiteley, Mohr-Davidow Ventures

Sponsor/Organizer:
•Gutenberg Communications: Suzanne Matick, Principal, Los Gatos Office

Churchill Club
Thursday January 22, 2009, Palo Alto, CA
www.churchillclub.org

Informatics: Personalized Medicine In An Era of Evidence Based Medicine

2009-09-02T06:58:05.460Z

Robert Mellins, MD, Columbia University School of Medicine, uses the asthma guidelines for clinical practice to illustrate the importance of personalizing medicine for optimal patient care. Series: "LeNoir - NMA Pediatric Lecture Series" [4/2008] [Health and Medicine] [Show ID: 13981]

Systems Biology: Georgia Tech's Center for the Study of Systems Biology with IBM

2008-10-11T18:20:04.334Z

Georgia Tech's Center for the Study of Systems Biology partners with IBM and Force 10 to build an Energy Efficient supercomputer with the IBM Cluster 1350 and BladeCenter LS20 servers. The new technology will enable Georgia Tech to find treatments to fight diseases faster than ever before.